

Minutes
September 27, 2004
Drug Utilization Review (DUR) Board

Members Present: Brendan Joyce, Scott Setzepfandt, Norm Byers, Bob Treitline, Al Samuelson, Gary Betting, Cheryl Huber, Greg Pfister, Leann Ness, John Savageau, Pat Churchill, Greg Pfister, Kamille Sherman (for part of the meeting)

Members absent: Jay Huber, Carrie Sorrenson

The Chair John Savageau called the meeting to order at 1:10 PM in the Pioneer Room. He asked for nominations for vice-chair. Norm Byers nominated Camille Sherman. Brendan Joyce stated that she asked to not be considered for this position. Greg Pfister nominated Al Samuelson. Cheryl Huber seconded the nomination. No other nominations were called for and John Savageau asked for a voice vote. All approved (no audible dissensions).

John Savageau asked for approval of the April 26th meeting minutes. Bob Treitline moved to approve the minutes as submitted. Cheryl Huber seconded. Voice vote and all approved (no audible dissensions). John Savageau asked for approval of the June 21st meeting minutes. Cheryl Huber moved to approve as submitted and Leann Ness seconded. Voice vote and all approved (no audible dissensions).

Brendan Joyce gave a budget update at the request of the chair. The appropriation through July 2004 was \$44,677,038 while expenditures were \$45,974,797. He stated that if the rebate collections would have been what was expected, the difference would have been closer to \$200,000.

John Savageau asked for an update on rules. Brendan Joyce shared a copy of the approved rules with the Board. There were no comments on the rules from the Board. Brendan Joyce explained some options as to how the form could be modified to accommodate the rules. Board members wanted copies of the current form to review while discussing the issue.

Andy McLean, MD came forward to present "Open Access" and the use and limitations of use of psychological medications for the mentally ill. The presentation is available if desired.

Brendan Joyce answered a number of questions regarding NDPPP (Comprehensive Neurosciences program).

Wellbutrin XL was discussed. A representative from GlaxoSmithKline presented information regarding the medication. A roll call vote was held on the pending motion. Leann Ness abstained. Norm Byers and Pat Churchill voted in favor of the pending motion. Cheryl Huber, Al Samuelson, Bob Treitline, Greg Pfister, and John Savageau voted against the motion, so the motion failed 5-2 with one abstaining (Kamille Sherman had dropped off of the conference call by this time). John Savageau and Bob Treitline asked that this topic be looked at again in the future.

John Savageau started discussion for the DAW form review. Brendan Joyce verbally explained the format of the form taking into account the earlier discussions. Overall, the format would remain close to the same as the existing forms, with fill-in-the-blank for the drug requested, the qualifications for coverage would include a check-box for failed generic equivalent, adverse reaction to generic, and a third section to accommodate the change in the rules. Bob Treitline moved to approve the proposed form. Norm Byers seconded the motion. A voice vote was held with all approving (no audible dissensions).

John Savageau called on Scott Setzapfandt to present on behalf of Roche for orlistat. Scott Setzapfandt excused himself from the Board until after the end of this topic. He presented information and handouts (available upon request). The Board discussed the information and decided to take no action to change the criteria for coverage.

John Savageau asked Linda Wurtz to speak to the Board regarding the Oregon Project. She asked if she could bring a representative from the Oregon Project to speak at an upcoming meeting and she gave a quick overview of the project. John Savageau stated that he would like to hear someone from the Oregon Project present more information to the Board.

John Savageau moved the Board to the lone item of new business, ACE inhibitors. Brendan Joyce mentioned that this is often the 'next class' of medications addressed by states as they roll out prior authorization. John Savageau expressed concerns that ARB use could increase if ACE inhibitors were prior authorized which could lower the standard of care for some patients in certain cases. After much discussion, the Board decided to look at both classes in the next meeting.

Agenda items for the upcoming meeting were discussed and the agenda will be sent out after the Chair works with the Department to finalize it. John Savageau asked for a motion to adjourn, and the meeting was adjourned at 3 pm.